

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

Editorial Office: International Institute
of Anticancer Research,
1st km Kapandritiou - Kalamou Rd.,
Kapandriti, P.O.Box 22, Attiki 19014,
Greece
Fax: 0030-22950-53389
Tel: 0030-22950-52945
e-mail: journals@iiar-anticancer.org

Dear Sir/Madam,

Please find the enclosed galley proofs of your article. Below are instructions on how to help facilitate the timely publication of your article in ANTICANCER RESEARCH.

1. Please read, correct and return the proofs to the Editorial Office within 2-3 working days.
2. Proofs may be Faxed, e-mailed or returned by the fastest mail available. Delays in the return of your proofs may necessitate transferring your paper to a later issue of the journal.
3. While reviewing your manuscript, please be on the lookout for unintended changes in the meaning of the text through editorial corrections or language improvements.
4. With the exception of the above, corrections should be limited to typographical errors.
5. To promote our rapid publication policy, figures are not sent to authors unless alterations have been made through the editing process.
6. **Should you require extra reprints of your article, please order them now.** Reprints ordered at this time will reach you considerably faster than if ordered after the publication of your article.
7. For further information on your article (publication date, volume, page numbers *etc.*), please contact the Editorial Office by Fax/Tel: 0030-22950-53389, e-mail: journals@iiar-anticancer.org, or by sending a letter to the Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou - Kalamou Rd., Kapandriti, P.O.Box 22, Attiki 19014, Greece.
8. In all correspondence with us please provide your manuscript number, your complete postal address, telephone/fax numbers and e-mail address.

Thank you for taking the time to study these guidelines.

Yours,



J.G. Delinassios
Managing Editor

Enclosures

Clinical and Dermoscopic Criteria Related to Melanoma Sentinel Lymph Node Positivity

GIANLUCA PAGNANELLI¹, RICCARDO BONO¹, MARIA A. PIZZICHETTA², RENATO TALAMINI²,
PAOLO A. ASCIERTO³, ALESSANDRO TESTORI⁴ and IGNAZIO STANGANELLI⁵,
on behalf of the Italian Melanoma Intergroup (IMI)

¹Istituto Dermatologico dell'Immacolata, IRCCS, Roma;

²Centro di Riferimento Oncologico, CRO, Aviano;

³Istituto Nazionale Tumori "Pascale", Napoli;

⁴Melanoma Unit, Istituto Europeo Oncologico, Milan and

⁵Skin Cancer Unit, CPO, Ravenna and Niguarda Hospital, Milan, Italy

Abstract. *Background:* The early detection of lymph node metastases may have important prognostic and therapeutic implications in melanoma patients. The purpose of this study was to investigate whether specific clinical and/or dermoscopic features could be "in vivo" predictors of sentinel lymph node (SLN) positivity in melanomas >1 mm thick. *Materials and Methods:* Five Italian centres (Istituto Dermatologico dell'Immacolata, IDI, Rome; Skin Cancer Unit, Oncologia Dermatologica, CPO, Ravenna; Istituto Europeo Oncologico, Milan; Centro di Riferimento Oncologico, Aviano; Istituto Nazionale Tumori, Naples) carried out a blind retrospective study on 508 melanomas observed from January 1994 to December 2002. The clinical and dermoscopic features of 78 melanomas >1 mm thick with the SLN biopsied were reviewed. *Results:* The tumour palpability was the only factor correlated to SLN positivity in melanomas >1 mm thick. Palpability was found in 46.2% of nodal positive melanomas and in 18.5% of nodal negative melanomas ($p=0.03$). The patients with palpable melanomas showed a higher risk of nodal metastasis ($OR=3.8$). Dermoscopy failed to recognize predictive criteria for SLN positivity. Some clinical and dermoscopic features, although not statistically significant, showed interesting differences between nodal-negative and nodal-positive melanomas. *Conclusion:* Melanoma palpability may suggest the presence of nodal metastasis in >1 mm thick tumours.

Correspondence to: Gianluca Pagnanelli, MD, Department of Dermo-immuno-oncology, Istituto Dermatologico Immacolata - IRCCS, Via dei Monti di Creta, 104 - 00167, Rome, Italy. Tel: +39 06 66462281, Fax: +39 06 66464492, e-mail: g.pagnanelli@idi.it

Key Words: Melanoma, sentinel lymph node, lymphatic mapping, dermoscopy, TNM staging system.

In 2002, the American Joint Committee on Cancer revised the TNM staging system for cutaneous melanoma on the basis of important emerging prognostic evidence in melanoma patients (1). The new TNM classification included some fundamental changes: the Breslow thickness was considered to be the most important survival indicator in patients with localized melanoma; a new thickness threshold of 1.0 mm defined the T1/T2 stage, set at 0.75 mm in the previous (1997) version; the presence of ulceration (evidenced histopathologically) or a Clark level IV/V, upstaged the tumour to the next T level; the number of lymph nodes involved rather than their dimension was considered to be the primary determinant in N staging; the lymphatic mapping and the sentinel lymph node (SLN) biopsy were established as highly accurate techniques in pathological regional nodal staging that allow the selective application of SLN dissection only in node-positive melanoma patients (2).

Historically tumour thickness (3) and more recently the SLN involvement (2) have been considered as the most powerful prognostic indicators in melanoma patients.

Dermoscopy (dermatoscopy, epiluminescence microscopy, incident light microscopy and surface microscopy) is a useful and non-invasive technique for early melanoma detection (4). Dermoscopy reveals skin features, otherwise invisible to the naked-eye, correlated to specific histological characteristics (5). Since some dermoscopic criteria, such as the pigment network, blue-grey areas and vascular patterns have been related to different tumour thicknesses, dermoscopy may have a role in the pre-operative assessment of melanoma thickness and may be an indication for SLN biopsy (6-8).

The purpose of this study was to investigate whether specific clinical and/or dermoscopic features could be "in vivo" predictors of SLN positivity in >1 mm thick melanoma patients. A secondary objective was to identify melanoma patients, currently not routinely considered for

SLN biopsy, at sufficient risk of metastasis to justify extended indications for SLN biopsy.

Patients and Methods

The five Italian centres included in this multicentric retrospective study (Istituto Dermopatico dell'Immacolata, IDI, Rome; Skin Cancer Unit, Oncologia Dermatologica, CPO, Ravenna; Istituto Europeo Oncologico, Milan; Centro di Riferimento Oncologico, Aviano and Istituto Nazionale Tumori, Naples) reviewed a total of 508 melanomas observed in 494 patients (221 males and 273 females) between January 1994 and December 2002. Three hundred and ninety-one melanomas were ≤ 1 mm (77%) and 117 melanomas > 1 mm (23%) thick. Fourteen patients had two or more melanomas. The patients with multiple and/or ulcerated melanoma, as well as the patients with incomplete clinical and/or dermoscopic data were not included in the study. The Clark level was not used for SLN biopsy selection. Seventy-eight melanoma cases (42 males and 36 females) thicker than 1 mm which had undergone SLN biopsy were included in this study.

A clinical data sheet for each patient was completed and reported age (< 40 , 40-49, 50-59, and > 60 years), gender (M/F), previous melanoma (yes or no), tumor site (trunk, lower limbs, upper limbs), shape (symmetric/asymmetric), colour (black, one colour, ≤ 3 colours, > 3 colours or colourless), thickness (flat or palpable), borders (sharp or partly sharp) and presence of regression (yes or no). Melanoma dermoscopic images were acquired and stored on a compact disc as jpeg files; 438 images were taken with a digital stereomicroscope and 70 with a Dermaphot camera (Heine Optotechnik; Herrsching, Germany) (x10 magnification) and then digitalized with the Kodak PhotoCD system. The digital stereomicroscope system consisting of a stereomicroscope and a Sony 3CCD DXC-930P colour video camera, produced digital images with a magnification range from 16x to 25x. Three experts in dermoscopy (M.A.P., R.B. and I.S.) evaluated and registered the dermoscopic features of each melanoma, including pigment network (absent, typical or atypical), radial streaks (absent or present), pseudopodes (absent or present), pigmentation (absent, regular or irregular), brown globules (absent or present), pink globules (absent or present), black dots (absent or present), blue-whitish veil (absent or present), regression (absent or present), hypopigmentation (absent or present) and vascular pattern (absent, regular or irregular). The presence or absence of clinical and dermoscopic criteria were defined by a 2/3 or unanimous agreement.

Chi-square test was used to evaluate differences for the qualitative parameters (9). The differences between subgroups were also computed by odd ratios (OR) and corresponding 95% confidence interval (CI) (10). The results were considered to be statistically significant at $p \leq 0.05$ (two-sided).

Results

The distribution of 78 melanomas > 1 mm thick by negative (65 cases) and positive (13 cases) SLN histopathological diagnosis according to age, gender and site is reported in Table I. The percentage of nodal metastasis was 16.6%. The median age was 55 years (range: 22-83) for the patients with negative SLN and 54 years (range: 33-84) for the patients

Table I. Age, gender and sites of 78 melanomas subjected to SLN biopsy according to histological diagnosis of sentinel lymph node.

	Histological diagnosis of sentinel lymph-node			
	Negative (n=65)		Positive (n=13)	
	N.	(%)	N.	(%)
Age (years)				
<40	16	(24.6)	1	(7.7)
40-49	9	(13.9)	3	(23.0)
50-59	17	(26.1)	4	(30.8)
≥ 60	23	(35.4)	5	(38.5)
Gender				
Male	34	(52.3)	8	(61.5)
Female	31	(47.7)	5	(38.5)
Site				
Trunk	37	(56.9)	9	(69.2)
Lower limbs	21	(32.3)	3	(23.1)
Upper limbs	7	(10.8)	1	(7.7)

with nodal metastasis. There were no differences in the age, gender and site distribution percentages.

Table II compares the clinical features of melanomas with and without nodal metastasis. Palpable thickness was more likely to be present in melanomas with positive SLN than in those with negative SLN (46.2% and 18.5% respectively). Moreover patients with palpable melanomas had a significantly higher risk (OR=3.8; 95% CI: 1.1-13.3; $p \leq 0.03$) for nodal metastasis than those with flat melanomas. The other clinical features, such as the melanoma site, shape, colour, borders and regression did not show any significant differences between tumors with negative and positive SLN.

Table III compares the dermoscopic features of melanomas with and without nodal metastasis. Although some features such as the presence of pseudopodes and regression showed interesting differences between these groups of cases, they were however not significant.

Discussion

The most important aim of the non-invasive methods used to measure melanoma thickness is to differentiate thin (≤ 1 mm) from thick (> 1 mm) lesions and then to perform SLN biopsy only on the latter. The current use of SLN biopsy is considered appropriate only for patients with non-palpable lymph nodes and melanoma thickness of more than 1 mm, or ulcerated, or Clark level IV/V (11). For thin melanomas the risk of regional lymph node metastasis is very low (12) and the SLN biopsy is not commonly performed. Patients with thick melanoma have a 20-25% incidence of microscopic regional disease (13) and SLN biopsy is performed in order to estimate the prognosis and the need for adjuvant therapy.

Table II. Clinical features of 78 melanomas subjected to SLN biopsy according to histological diagnosis of sentinel lymph node.

	Histological diagnosis of sentinel lymph-node			
	Negative (n=65)		Positive (n=13)	
	N.	(%)	N.	(%)
Previous melanoma				
No	57	(87.7)	12	(92.3)
Yes	8	(12.3)	1	(7.7)
Thickness				
Flat	53	(81.5)	7	(53.8)
Palpable	12	(18.5)	6	(46.2) ¹
Shape				
Symmetric	21	(32.3)	3	(23.1)
Asymmetric	44	(67.7)	10	(76.9)
Borders				
Sharp	30	(46.2)	8	(61.5)
Partly sharp	35	(53.8)	5	(38.5)
Colour				
One colour	34	(52.3)	7	(53.9)
Two or more colours	30	(46.2)	6	(46.2)
Colourless	1	(1.5)	--	
Regression				
No	39	(60.0)	10	(76.9)
Yes	26	(40.0)	3	(23.1)

¹In comparison with the negative histological diagnosis of SLN *p* value of the Chi-square test was 0.03, odds ratio (OR) was 3.8 (95% CI: 1.1-13.3).

Several factors have been reported to have a predictive value for SLN metastasis (3, 14, 15), including Breslow thickness, Clark level, ulceration, mitotic rate, microsatellitosis, angiolymphatic invasion, primary tumour location and patient age. The Breslow thickness is the only reproducible factor predictive of SLN status in all studies (16) and is still considered to be the most powerful independent prognostic factor in localized cutaneous melanoma (17-20). The Clark level is an independent predictive feature in thin melanoma but not for thicker lesions (21). Ulceration was not included in the previous staging system, but in the new version it is considered to be the second strongest prognostic factor in primary melanoma and the only primary tumour factor to modify the prognosis of node-positive disease (1). Ulceration can be clinically difficult to distinguish from artifactual or traumatic disruption of the epidermis, but it is easy to recognize with histopathology (1). It has not been considered in our study because of the impossibility of defining the dermoscopic features of ulcerated melanomas and its well-established importance in melanoma prognosis.

A high mitotic rate, calculated as >5 mitosis per square millimeter (22), has been reported as an independent

Table III. Dermoscopic criteria of 78 melanomas subjected to SLN biopsy according to histological diagnosis of sentinel lymph node.

	Histological diagnosis of sentinel lymph-node			
	Negative (n=65)		Positive (n=13)	
	N.	(%)	N.	(%)
Pigment network				
Absent	40	(61.5)	10	(76.9)
Atypical	25	(38.5)	3	(23.1)
Radial streaks				
Absent	46	(70.8)	10	(76.9)
Present	19	(29.2)	3	(23.1)
Pseudopodes				
Absent	49	(75.4)	13	(100.0)
Present	16	(24.6)	--	--
Pigmentation				
Absent/regular	5	(7.7)	3	(23.1)
Irregular	60	(92.3)	10	(76.9)
Brown globules				
Absent	23	(35.4)	7	(53.9)
Present	42	(64.6)	6	(46.2)
Pink globules				
Absent	53	(81.5)	13	(100.0)
Present	12	(18.5)	--	--
Black dots				
Absent	17	(26.2)	3	(23.1)
Present	48	(73.8)	10	(76.9)
Blue-whitish veil				
Absent	17	(26.2)	2	(15.4)
Present	48	(73.8)	11	(84.6)
Regression				
Absent	25	(38.5)	7	(53.8)
Present	40	(61.5)	6	(46.2)
Hypopigmentation				
Absent	54	(83.1)	9	(69.2)
Present	11	(16.9)	4	(30.8)
Vascular patterns				
Absent	49	(75.4)	10	(76.9)
Atypical	16	(24.6)	3	(23.1)

prognostic predictor of lymph node positivity in melanoma patients (23-25).

Microsatellites, reported as tumor nests >0.05 mm separated from the original melanoma by normal tissue (26), have been associated with an increased frequency of regional lymph node metastasis, although they rarely occur in tumours of <1.5 mm.

Angiolymphatic invasion is rarely present in non-metastatic melanomas, while it has been reported in 57% of nodular melanomas with SLN positivity (27).

Some studies have shown that a young age is an independent factor associated with an increased likelihood of nodal melanoma metastasis (23). Conversely some data have emphasized old patients as being more likely to

present with thicker and ulcerated melanomas and generally the survival rate decreases as the patient's age increases (28). Many studies have reported that women have a better prognosis, even in patients with nodal metastasis (18, 29-31). In another study the male gender has been correlated to nodal disease in thin melanoma patients (32). Some primary tumour locations, such as head, neck and trunk have been correlated to a worse prognosis when compared with a melanoma of the extremities (18, 29, 30).

Our results from patients with melanoma thickness >1 mm showed that the patient's age and gender, and the location of the primary tumour did not significantly influence the SLN status, although in the middle-aged patients (40-49 years) the percentage of positive SLN (23.0%) was higher than in those with negative SLN (13.9%), and males seems more likely to present SLN metastasis (61.5% vs. 38.5% in females).

To date relatively few studies have examined the relationship between clinical palpability and melanoma thickness, and very few between clinical palpability and SLN status. Although previous reports have demonstrated a direct correlation between palpability and melanoma thickness (33-35), other authors did not confirm it (36). In most of these studies a 0.75 mm thickness threshold from the "old" TNM staging system has been used to distinguish the "thin" from "thick" melanoma. Melanoma palpability has recently been reconsidered by Argenziano *et al.* for the construction of an algorithm of combined clinical and dermoscopic criteria which would allow a predictive value for melanomas >0.75 mm in 89% of cases. The predictive value of palpability alone was correct in 62% (37). According to Argenziano *et al.*, a lesion was considered to be palpable in the present study when it was obviously discernable by touch, nodular or at least papular. In our study palpability showed a statistically significant correlation with SLN positivity and was found in 46.2% of SLN positive melanomas and in 18.5% of SLN negative tumours.

Although regression is frequently observed in primary melanomas and especially in thin lesions, accounting for 10 to 35% of all melanoma cases (38) and up to 58% of those with a thickness <0.75 mm (39), its prognostic significance is still controversial. Histopathology may underestimate the real Breslow thickness of a melanoma with regression because of tumour cell replacement by inflammatory cells and fibrosis (40). On the other hand regression may reflect a good host immune response to tumour cells. Many authors have claimed that regression has no adverse effect on the SLN positivity (41, 42), others regard it as a sign of poor prognosis (43, 44) and in a recent study the SLN status seems more favourable in the presence of regression (45). Our study results seem to validate the latter since evidence of clinical regression was present in 40% of >1 mm melanomas with negative SLN and in 23.1% of those with positive SLN and dermoscopic signs of regression were

found in 61.5% of negative SLN melanomas and in 46.2% of positive SLN tumours.

In our experience dermoscopy failed to recognize statistically significant predictive criteria for SLN positivity in melanomas >1 mm thick. Specific melanoma criteria strongly associated with a higher Breslow thickness such as grey-blue areas or an atypical vascular pattern (6) were not correlated to SLN positivity. The blue-whitish veil was found in 84.6% of SLN positive melanomas and in 73.8% SLN negative tumours, an atypical vascular pattern was present in 23.1% of SLN positive melanomas and in 24.6% SLN negative tumours. The low prevalence of malignant epidermal structures such as an atypical pigment network, radial streaks and pseudopods in melanomas >1 mm thick was closely related to the dermal proliferation activity (8). The pigment network and the relative peripheral extension expressed by radial streaks and pseudopods appeared to be inversely proportional to the Breslow thickness, most likely due to increased infiltration, dis-aggregation and compression of the rete ridges (6, 8, 46). In our experience the malignant epidermal structures were more frequent in SLN negative melanomas when compared to SLN positive melanomas (atypical pigment network in 38.5% vs. 23.1%, radial streaks in 29.2% vs. 23.1%, respectively). Furthermore, no SLN positive melanoma showed pseudopods, while they were present in 24.6% of SLN negative melanomas. Nevertheless no statistically significant differences were recorded.

Palpability was the only factor correlated to SLN positivity, among the clinical and dermoscopic features considered in the present study, in melanomas >1 mm thick. Furthermore, in patients with palpable melanoma there was a 3.8 higher risk of finding SLN metastasis when compared with non-palpable melanoma patients. Our results seem to rehabilitate the role of melanoma palpability as a useful and simple clinical indication of SLN positivity in melanomas >1 mm thick. It is easy to recognize, reproducible and objective.

Further investigation on a larger number of cases is needed to verify our results and to confirm the role of palpability as an independent prognostic factor in thick melanomas.

References

- 1 Balch CM, Buzaid AC, Soong SJ *et al*: New TNM melanoma staging system: linking biology and natural history to clinical outcomes (review). *Semin Surg Oncol* 21: 43-52, 2003.
- 2 Rousseau DL Jr and Gershenwald JE: The new staging system for cutaneous melanoma in the era of lymphatic mapping (review). *Semin Oncol* 31: 415-425, 2004.
- 3 Balch CM, Soong S, Shaw HM *et al*: An analysis of prognostic factors in 8500 patients with cutaneous melanoma. *In*: Cutaneous Melanoma, Balch CM, Houghton AN and Milton GW (eds.). Philadelphia: JB Lippincott, pp. 165-176 1992.
- 4 Pagnanelli G, Soyer HP, Argenziano G *et al*: Diagnosis of pigmented skin lesions by dermoscopy: web-based training

- improves diagnostic performance of non-experts. *Br J Dermatol* 148: 698-702, 2003.
- 5 Soyer HP, Kenet RO, Wolf IH *et al*: Clinicopathological correlation of pigmented skin lesions using dermoscopy. *Eur J Dermatol* 10: 22-28, 2000.
 - 6 Argenziano G, Fabbrocini G, Carli P *et al*: Epiluminescence microscopy: criteria of cutaneous melanoma progression. *J Am Acad Dermatol* 37: 68-74, 1997.
 - 7 Carli P, De Giorgi V, Palli D *et al*: Preoperative assessment of melanoma thickness by ABCD score of dermoscopy. *J Am Acad Dermatol* 43: 459-466, 2000.
 - 8 Stanganelli I, Zago S, Testori A *et al*: Epiluminescence microscopy features of melanoma in relation to tumor thickness. *Current concepts and clinical examples. Dermatol Clin* 19: 285-297, 2001.
 - 9 Armitage P and Berry G: *Statistical Methods in Medical Research*. Blackwell Sc. Publication, 1987.
 - 10 Breslow NE and Day NE: *Statistical methods in cancer research. Vol. I - The analysis of case-control studies*. Lyon: IARC Scientific Publications No. 32, 1980.
 - 11 Scheri RP and Essner R: Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma (review). *Expert Rev Anticancer Ther* 6: 1105-1110, 2006.
 - 12 Ranieri JM, Wagner JD, Wenck S, Johnson CS and Coleman JJ 3rd: The prognostic importance of sentinel lymph node biopsy in thin melanoma. *Ann Surg Oncol* 13: 927-32, 2006.
 - 13 Shapiro RL: *Surgical approaches to malignant melanoma. Practical guidelines (review)*. *Dermatol Clin* 20: 681-699, 2002.
 - 14 Balch CM, Houghton AN, Sober AJ and Soong SJ (eds). *Cutaneous Melanoma*. St. Louis: Quality Medical Publishing, pp. 551-571, 1998.
 - 15 Testori A, Lazzaro G, Baldini F *et al*: The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. *Melanoma Res* 15: 191-198, 2005.
 - 16 Jemal A, Thomas A, Murray T and Thin M: *Cancer statistics, 2002*. *CA Cancer J Clin* 52: 23-47, 2002.
 - 17 Balch CM, Soong SJ, Gershenwald JE *et al*: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol* 19: 3622-3634, 2001.
 - 18 Schuchter L, Schultz DJ, Synnestvedt M *et al*: A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. *Ann Intern Med* 125: 369-375, 1996.
 - 19 Soong SJ, Shaw HM, Balch CM *et al*: Predicting survival and recurrence in localized melanoma: a multivariate approach. *World J Surg* 16: 191-195, 1992.
 - 20 Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. *Ann Surg* 172: 902-908, 1970.
 - 21 Balch CM, Soong SJ, Atkins MB *et al*: An evidence-based staging system for cutaneous melanoma. *CA Cancer J Clin* 54: 131-149, 2004.
 - 22 Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M *et al*: Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. *Arch Dermatol* 134: 983-987, 1998.
 - 23 Sondak VK, Taylor JM, Sabel MS *et al*: Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. *Ann Surg Oncol* 11: 247-258, 2004.
 - 24 Gimotty PA, Elder DE, Fraker DL, *et al*: Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. *J Clin Oncol* 25: 1129-1134, 2007.
 - 25 Nagore E, Oliver V, Botella-Estrada R *et al*: Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. *Melanoma Res* 15: 169-177, 2005.
 - 26 Day CL Jr, Harrist TJ, Gorstein F *et al*: Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. *Ann Surg* 194: 108-112, 1981.
 - 27 Straume O and Akslen LA: Independent prognostic importance of vascular invasion in nodular melanomas. *Cancer* 78: 1211-1219, 1996.
 - 28 Caraco C, Marone U, Botti G, Celentano E, Lastoria S and Mozzillo N: Age as predictor in patients with cutaneous melanoma submitted to sentinel lymph node biopsy. *Eur J Surg Oncol* 32: 970-973, 2006.
 - 29 Masback A, Olsson H, Wester Dahl J *et al*: Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. *Melanoma Res* 11: 435-445, 2001.
 - 30 Slingluff CL Jr, Vollmer RT, Reintgen DS and Seigler HF: Lethal "thin" malignant melanoma. Identifying patients at risk. *Ann Surg* 208: 150-161, 1988.
 - 31 Vossaert KA, Silverman MK, Kopf AW *et al*: Influence of gender on survival in patients with stage I malignant melanoma (review). *J Am Acad Dermatol* 26: 429-440, 1992.
 - 32 Gimotty PA, Guerry D, Ming ME *et al*: Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. *J Clin Oncol* 22: 3668-3676, 2004.
 - 33 Kopf AW, Welkovich B, Frankel RE *et al*: Thickness of malignant melanoma: global analysis of related factors. *J Dermatol Surg Oncol* 13: 345-390 and 401-420, 1987.
 - 34 Taylor BA and Hughes LE: A policy of selective excision for primary cutaneous malignant melanoma. *Eur J Surg Oncol* 11: 7-13, 1985.
 - 35 Funk W, Schmoeckel C, Holzel D and Braun-Falco O: Prognostic classification of malignant melanoma by clinical criteria. *Br J Dermatol* 111: 129-138, 1984.
 - 36 O'Donnell BF, Marsden JR, O'Donnell CA *et al*: Does palpability of primary cutaneous melanoma predict dermal invasion? *J Am Acad Dermatol* 34: 632-637, 1996.
 - 37 Argenziano G, Fabbrocini G, Carli P *et al*: Clinical and dermatoscopic criteria for the preoperative evaluation of cutaneous melanoma thickness. *J Am Acad Dermatol* 40: 61-68, 1999.
 - 38 Fontaine D, Parkhill W, Greer W and Walsh N: Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? *Am J Dermatopathol* 25: 371-376, 2003.
 - 39 McGovern VJ, Shaw HM and Milton GW: Prognosis in patients with thin malignant melanoma: influence of regression. *Histopathology* 7: 673-680, 1983.
 - 40 Paladugu RR and Yonemoto RH: Biologic behaviour of thin malignant melanomas with regressive changes. *Arch Surg* 118: 41-44, 1983.
 - 41 Trau H, Rigel DS, Harris MN *et al*: Metastases of thin melanomas. *Cancer* 51: 553-556, 1983.
 - 42 Weissmann A, Roses DF, Harris MN and Dubin N: Prediction of lymph node metastases from the histologic features of

- primary cutaneous malignant melanomas. *Am J Dermatopathol 6 Suppl*: 35-41, 1984.
- 43 Naruns PL, Nizze JA, Cochran AJ, Lee MB and Morton DL: Recurrence potential of thin primary melanomas. *Cancer 57*: 545-548, 1986.
- 44 Sondegard K and Hou-Jensen K: Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases. *Virchows Arch A Pathol Anat Histopathol 408*: 241-247, 1985.
- 45 Liszkay G, Orosz Z, Peley G *et al*: Relationship between sentinel lymph node status and regression of primary malignant melanoma. *Melanoma Res 15*: 509-513, 2005.
- 46 Stolz W, Semmelmayr U, Johow K and Burgdorf WH: Principles of dermatoscopy of pigmented skin lesions. *Semin Cutan Med Surg (review) 22*: 9-20, 2003.

Received January 31, 2007

Revised May 7, 2007

Accepted May 9, 2007

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

May 9, 2007

Dr. Gianluca Pagnanelli

Re: Your manuscript No. **7832-P** entitled «**Clinical and Dermoscopic Criteria...**»

Dear Dr

Referring to your above manuscript for publication in AR, please allow us to use this form letter in reply:

1. *Referee's recommendations:*

- Urgent to be published immediately.
- Accepted in the presented form.
- Accepted with minor changes.
- Accepted with grammatical or language corrections.
- Remarks: 1) **Please provide all names for all references**
2) **In Table 2: please explain where superscript 1 refers to**

2. *Excess page charges.*

- Your article has approx. **6** printed pages and is in excess of the allotted number by approx. **2** printed pages. The charges are EURO € **180** per excess page, totalling EURO € **180 (-50% Discount)**
We ask you to confirm acceptance of these charges.
- Your article includes pages with color figures. The charges are EURO € per color page, totalling EURO €
- Our invoice is sent by air mail to the corresponding author.

3. Your article will appear in Volume **27**, Issue No. **4, 2007**

4. Please order your reprints now. This will facilitate our prompt planning of future issues and rapid publication of your article. Reprints will be delivered by air mail within one month from publication.

We would appreciate your prompt reply.

With many thanks,

Yours sincerely,



J.G. Delinassios
Managing Editor

EDITORIAL OFFICE: INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH
1st km Kapandritiou - Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece. Tel.: 0030-22950-52945;
Tel & Fax:0030-22950-53389; e-mail: journals@iiar-anticancer.org

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

Editorial Office: International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece
Fax: 0030-22950-53389; Tel: 0030-22950-52945; e-mail: journals@iiar-anticancer.org

ISSN: 0250-7005

Please type or print the requested information on the reprint order form and return it to the Editorial Office by fax or e-mail.

Reprints must be paid for in advance.

If your paper is subject to charges for excess pages or color plates, please add these charges to the payment for reprints.

The reprints are not to be sold.

PRICE LIST FOR REPRINTS WITHOUT COVER

Page length	PDF file	Number of copies requested (prices are in Euro)									
		100	200	300	400	500	1000	1500	2000	3000	5000
1-4pp	167	335	387	438	503	554	851	1135	1470	2038	3225
5-8	219	438	503	580	645	722	1083	1445	1832	2554	4012
9-12	277	554	619	709	787	877	1341	1780	2219	3096	4824
13-16	354	709	787	890	993	1096	1625	2141	2657	3676	5715
17-20	419	838	929	1032	1148	1277	1883	2451	3044	4244	6527

For reprints with cover: Please add EURO 140.00 per 100 copies.

Postage: Please add 4% on the above prices.

Reprint Order Form

Of my paper No. **7832-P** comprising **6** printed pages, entitled «**Clinical and Dermoscopic Criteria...**» accepted for publication in ANTICANCER RESEARCH Vol. **27** No. **4**

- I require a total of _____ copies at EURO _____
- I do not require reprints.
- Please send me a PDF file of the article.
- Please send me a copy of this issue containing my paper at EURO 45.00.
- Please enter my personal subscription to ANTICANCER RESEARCH at the special Author's price of EURO 400.00 (Year: 2007).
- A check for the above amounts payable to J.G. Delinassios, Executive Publisher of Anticancer Research Journal, is enclosed.
- Please send an invoice to:

For EC countries: Please give your VAT number:

City and Date:

Exact postal address:

Tel:

Fax:

Signature: